260 related articles for article (PubMed ID: 23434636)
1. Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents.
El-Nassan HB
Eur J Med Chem; 2013 Apr; 62():614-31. PubMed ID: 23434636
[TBL] [Abstract][Full Text] [Related]
2. Receptor-ligand interaction-based virtual screening for novel Eg5/kinesin spindle protein inhibitors.
Nagarajan S; Skoufias DA; Kozielski F; Pae AN
J Med Chem; 2012 Mar; 55(6):2561-73. PubMed ID: 22309208
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of new KSP-Eg5 inhibitors assisted by a targeted multicomponent reaction.
Carbajales C; Prado MÁ; Gutiérrez-de-Terán H; Cores A; Azuaje J; Novio S; Nuñez MJ; Fernández-García B; Sotelo E; García-Mera X; Sánchez-Lazo P; Freire-Garabal M; Coelho A
Chembiochem; 2014 Jul; 15(10):1471-80. PubMed ID: 24943831
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship of pyrazolo pyrimidine derivatives as inhibitors of mitotic kinesin Eg5 and anticancer agents.
Muthuraja P; Veeramani V; Prakash S; Himesh M; Venkatasubramanian U; Manisankar P
Bioorg Chem; 2019 Mar; 84():493-504. PubMed ID: 30594885
[TBL] [Abstract][Full Text] [Related]
5. Progress on kinesin spindle protein inhibitors as anti-cancer agents.
Zhang Y; Xu W
Anticancer Agents Med Chem; 2008 Aug; 8(6):698-704. PubMed ID: 18690830
[TBL] [Abstract][Full Text] [Related]
6. Eg5 inhibitor YL001 induces mitotic arrest and inhibits tumor proliferation.
Wang Y; Wu X; Du M; Chen X; Ning X; Chen H; Wang S; Liu J; Liu Z; Li R; Fu G; Wang C; McNutt MA; Zhou D; Yin Y
Oncotarget; 2017 Jun; 8(26):42510-42524. PubMed ID: 28489567
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5.
Debonis S; Skoufias DA; Indorato RL; Liger F; Marquet B; Laggner C; Joseph B; Kozielski F
J Med Chem; 2008 Mar; 51(5):1115-25. PubMed ID: 18266314
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5.
Kaan HY; Weiss J; Menger D; Ulaganathan V; Tkocz K; Laggner C; Popowycz F; Joseph B; Kozielski F
J Med Chem; 2011 Mar; 54(6):1576-86. PubMed ID: 21344920
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Novel Allosteric Eg5 Inhibitors Through Structure-Based Virtual Screening.
Zhang W; Zhai L; Lu W; Boohaker RJ; Padmalayam I; Li Y
Chem Biol Drug Des; 2016 Aug; 88(2):178-87. PubMed ID: 26864917
[TBL] [Abstract][Full Text] [Related]
10. Growth arrest and apoptosis induced by kinesin Eg5 inhibitor K858 and by its 1,3,4-thiadiazoline analogue in tumor cells.
Giantulli S; De Iuliis F; Taglieri L; Carradori S; Menichelli G; Morrone S; Scarpa S; Silvestri I
Anticancer Drugs; 2018 Aug; 29(7):674-681. PubMed ID: 29738338
[TBL] [Abstract][Full Text] [Related]
11. Impact of kinesin Eg5 inhibition by 3,4-dihydropyrimidin-2(1H)-one derivatives on various breast cancer cell features.
Guido BC; Ramos LM; Nolasco DO; Nobrega CC; Andrade BY; Pic-Taylor A; Neto BA; Corrêa JR
BMC Cancer; 2015 Apr; 15():283. PubMed ID: 25885813
[TBL] [Abstract][Full Text] [Related]
12. Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance.
Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2021 Feb; 184():114364. PubMed ID: 33310050
[TBL] [Abstract][Full Text] [Related]
13. The kinesin Eg5 inhibitor K858 induces apoptosis and reverses the malignant invasive phenotype in human glioblastoma cells.
Taglieri L; Rubinacci G; Giuffrida A; Carradori S; Scarpa S
Invest New Drugs; 2018 Feb; 36(1):28-35. PubMed ID: 28965307
[TBL] [Abstract][Full Text] [Related]
14. Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor.
Liu M; Yu H; Huo L; Liu J; Li M; Zhou J
Biochem Pharmacol; 2008 Jul; 76(2):169-78. PubMed ID: 18539263
[TBL] [Abstract][Full Text] [Related]
15. Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers.
Murase Y; Ono H; Ogawa K; Yoshioka R; Ishikawa Y; Ueda H; Akahoshi K; Ban D; Kudo A; Tanaka S; Tanabe M
Cancer Sci; 2021 Nov; 112(11):4641-4654. PubMed ID: 34510663
[TBL] [Abstract][Full Text] [Related]
16. The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells.
De Iuliis F; Taglieri L; Salerno G; Giuffrida A; Milana B; Giantulli S; Carradori S; Silvestri I; Scarpa S
Invest New Drugs; 2016 Aug; 34(4):399-406. PubMed ID: 26994617
[TBL] [Abstract][Full Text] [Related]
17. Dihydropyrazole and dihydropyrrole structures based design of Kif15 inhibitors as novel therapeutic agents for cancer.
Sebastian J
Comput Biol Chem; 2017 Jun; 68():164-174. PubMed ID: 28355588
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of human mitotic kinesin Eg5: characterization of the 4-phenyl-tetrahydroisoquinoline lead series.
Tarby CM; Kaltenbach RF; Huynh T; Pudzianowski A; Shen H; Ortega-Nanos M; Sheriff S; Newitt JA; McDonnell PA; Burford N; Fairchild CR; Vaccaro W; Chen Z; Borzilleri RM; Naglich J; Lombardo LJ; Gottardis M; Trainor GL; Roussell DL
Bioorg Med Chem Lett; 2006 Apr; 16(8):2095-100. PubMed ID: 16458511
[TBL] [Abstract][Full Text] [Related]
19. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells.
Marcus AI; Peters U; Thomas SL; Garrett S; Zelnak A; Kapoor TM; Giannakakou P
J Biol Chem; 2005 Mar; 280(12):11569-77. PubMed ID: 15653676
[TBL] [Abstract][Full Text] [Related]
20. Doing the methylene shuffle--further insights into the inhibition of mitotic kinesin Eg5 with S-trityl L-cysteine.
Abualhasan MN; Good JA; Wittayanarakul K; Anthony NG; Berretta G; Rath O; Kozielski F; Sutcliffe OB; Mackay SP
Eur J Med Chem; 2012 Aug; 54():483-98. PubMed ID: 22749640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
